Literature DB >> 21209774

Chemokines and Cancer Progression: A Qualitative Review on the Role of Stromal Cell-derived Factor 1-alpha and CXCR4 in Endometrial Cancer.

Ashley S Felix, Robert Edwards, Robert Bowser, Faina Linkov.   

Abstract

The goal of this paper was to examine the literature related to stromal cell-derived factor 1-alpha (SDF-1alpha) and its receptor CXCR4 in endometrial cancer, as expression of these biomarkers has been implicated in an aggressive phenotype in other common epithelial cancers. We conducted a qualitative review of all published studies examining the role of SDF-1alpha/CXCR4 in endometrial cancer progression and prognosis. Pubmed and Ovid MEDLINE databases were searched in order to identify relevant studies for this qualitative review. Four studies have examined the role of the SDF-1alpha/CXCR4 pathway on endometrial cancer progression. The findings were contradictory; two studies reported an inverse association between overexpression and mortality while two studies reported overexpression to be associated with hallmarks of aggressive endometrial cancer. Expression of stromal-derived proteins can potentially serve as biomarkers of aggressive disease as well as biomarkers for remission monitoring, however the endometrial cancer literature has lagged behind in this area. Furthermore, the current research suffers from lack of comparability among different studies due to the utilization of different tools and lack of common outcome definitions. Future studies in this area should use clinically meaningful protein expression categories, widely accepted outcome definitions, and larger samples of patients. Finally, although standard immunohistochemistry is a mainstay in tumor marker studies, automated detection methods may be more suitable as they do not rely on subjective interpretation.

Entities:  

Keywords:  CXCR4; Chemokines; Endometrial cancer; Stromal cell-derived factor 1-alpha; Tumor markers; Tumor microenvironment

Year:  2010        PMID: 21209774      PMCID: PMC2990490          DOI: 10.1007/s12307-010-0042-7

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  24 in total

1.  Back to the drawing board on immunohistochemistry and predictive factors.

Authors:  Donald Earl Henson
Journal:  J Natl Cancer Inst       Date:  2005-12-21       Impact factor: 13.506

Review 2.  Immunohistochemistry and quantitative analysis of protein expression.

Authors:  Melissa Cregger; Aaron J Berger; David L Rimm
Journal:  Arch Pathol Lab Med       Date:  2006-07       Impact factor: 5.534

3.  Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction.

Authors:  Hirohisa Tsukamoto; Kiyosumi Shibata; Hiroaki Kajiyama; Mikio Terauchi; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Clin Exp Metastasis       Date:  2007-06-21       Impact factor: 5.150

4.  Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mikio Terauchi; Kazuhiko Ino; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

5.  Prognostic significance of stromal versican expression in human endometrial cancer.

Authors:  J Kodama; T Kusumoto; N Seki; T Matsuo; Y Ojima; K Nakamura; A Hongo; Y Hiramatsu
Journal:  Ann Oncol       Date:  2006-10-25       Impact factor: 32.976

6.  Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis.

Authors:  S A Sohaib; S L Houghton; R Meroni; A G Rockall; P Blake; R H Reznek
Journal:  Clin Radiol       Date:  2007-01       Impact factor: 2.350

7.  Stromal cell-derived factor 1alpha stimulates human endometrial carcinoma cell growth through the activation of both extracellular signal-regulated kinase 1/2 and Akt.

Authors:  Dan Zhao; Xiao-Ping Li; Min Gao; Chao Zhao; Jian-liu Wang; Li-hui Wei
Journal:  Gynecol Oncol       Date:  2006-08-01       Impact factor: 5.482

8.  Stromal cell-derived factor-1alpha-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma.

Authors:  Yayoi Mizokami; Hiroaki Kajiyama; Kiyosumi Shibata; Kazuhiko Ino; Fumitaka Kikkawa; Shigehiko Mizutani
Journal:  Int J Cancer       Date:  2004-07-10       Impact factor: 7.396

9.  Growth and activation of PI-3K/PKB and Akt by stromal cell-derived factor 1alpha in endometrial carcinoma cells with expression of suppressor endoprotein PTEN.

Authors:  Xiao-ping Li; Dan Zhao; Min Gao; Chao Zhao; Jian-liu Wang; Li-hui Wei
Journal:  Chin Med J (Engl)       Date:  2006-03-05       Impact factor: 2.628

Review 10.  Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.

Authors:  Tanri Shiozawa; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.850

View more
  4 in total

1.  Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes.

Authors:  Ikuhiko Nakase; Nahoko Bailey Kobayashi; Tomoka Takatani-Nakase; Tetsuhiko Yoshida
Journal:  Sci Rep       Date:  2015-06-03       Impact factor: 4.379

2.  Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease.

Authors:  Esperanza Medina-Gutiérrez; María Virtudes Céspedes; Alberto Gallardo; Elisa Rioja-Blanco; Miquel Àngel Pavón; Laura Asensio-Puig; Lourdes Farré; Lorena Alba-Castellón; Ugutz Unzueta; Antonio Villaverde; Esther Vázquez; Isolda Casanova; Ramon Mangues
Journal:  Biomedicines       Date:  2022-07-12

3.  Expression of CXC chemokine receptor-4 and forkhead box 3 in neuroblastoma cells and response to chemotherapy.

Authors:  Jing Sun; Chen Feng; Weiwei Liao; Hao Zhang; Suoqin Tang
Journal:  Oncol Lett       Date:  2014-04-03       Impact factor: 2.967

Review 4.  Adipocytokines and disease progression in endometrial cancer: a systematic review.

Authors:  Irene Ray; Lisiane B Meira; Agnieszka Michael; Patricia E Ellis
Journal:  Cancer Metastasis Rev       Date:  2021-12-24       Impact factor: 9.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.